"Paxlovid's Limited Efficacy in Shortening Covid Symptoms for Vaccinated Adults Revealed"
TL;DR Summary
Full trial results published in the New England Journal of Medicine confirm that Pfizer's antiviral drug Paxlovid did not shorten Covid-19 symptoms in vaccinated adults and those at low risk for severe symptoms, despite being marketed as a treatment for the virus. The pill was granted full approval last May to treat mild-to-moderate Covid-19 in adults at high risk for developing severe symptoms.
- Paxlovid didn't shorten Covid symptoms in vaccinated adults, full trial results confirm Endpoints News
- Among fully vaccinated, study shows Paxlovid does not shorten symptoms University of Minnesota Twin Cities
- Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients Medpage Today
- Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports Nature.com
- Paxlovid is effective against Covid-19, but many people eligible for it are not getting it; it’s fre ... The Lexington Times
Reading Insights
Total Reads
1
Unique Readers
1
Time Saved
0 min
vs 1 min read
Condensed
54%
136 → 63 words
Want the full story? Read the original article
Read on Endpoints News